Peer review

This publication offers scientifically-vetted articles summarising the key findings presented at ESC Congress 2011.

Content is selected by the Congress Programme Committee Chair and all articles are written entirely from primary source data, and have been carefully peer-reviewed to ensure accuracy and integrity.

Among the many articles in this official peer review are the cardiovascular disease (CVD) improvements by preventing diabetes as well as reports on a number of clinical trials, including:

• Result from ARISTOTLE
• Apixaban superior to Warfarin for prevention of SSE in patients with AF
• Findings from a sub analysis of DATA from the ARISTOTLE Trial
• Safety and tolerability of the Oral Xa Inhibitor Darexaban in patients with ACS: The RUBY-1 Trial
• Results from the EMPHASIS-HF Trial
• The PRODIDGY Trial – More information about DAPT after DES Implantation
• PURE: CV Drugs underused for secondary prevention in poor and rural populations
• The Homburg cream and sugar study: Postprandial triglycerides and risk in patients with CVD
• Results from the EXAMINATION Trial
• Results from the CRISP AMI Trial
• New observations from the STICH Trial
• New findings from the ASCOT LLA trial
• An Exploratory Analysis from IRIS
• Results of a Subanalysis from the RE-LY Trial
• New findings from ROCKET AF
• Results from the ONTARGET Trial

Included in the peer review are therapeutic updates such as TAVI, Lipids and Atrial Fibrillations, as well as the ESC Clinical Practice Guidelines 2011 overview, or new options for improving DAPT and stent implantation, pitfalls in Troponin evaluation, or finally a question of the effects of treatment in women and possible differences.

The quality and scope of the publication presenting the abstracts at this year’s ESC Congress 2011 show that it continues to be an innovative and informative forum for cardiologists. Top research and evidence-based reporting such as the ARISTOTLE trial or the PRODIGY trial were extensively presented in this past conference.